Balanced Outlook for Healthequity Amid Strong Performance and Economic Uncertainty Justifies Hold Rating

Analyst Sean Dodge of BMO Capital maintained a Hold rating on Healthequity, retaining the price target of $100.00.

Sean Dodge has given his Hold rating due to a combination of factors influencing Healthequity’s current and future performance. The company reported stronger-than-expected revenue and EBITDA for F3Q26, with management subsequently raising its FY26 guidance. Despite these positive results, the updated revenue guidance remains slightly below consensus, indicating some caution in the company’s outlook.
Additionally, while Healthequity has shown improvements in reducing fraud costs and enhancing operational efficiencies, these gains are tempered by the finite benefits from re-pricing cash assets at higher interest rates. The company is also preparing to unveil its FY27 targets, which may include new opportunities in the retail marketplace. However, the broader economic environment, including a potential decline in interest rates, suggests a balanced view on the stock’s potential, justifying the Hold rating.

HQY’s price has also changed slightly for the past six months – from $103.760 to $98.640, which is a -4.93% drop .